Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CDXS
SellSinkerCodexis, Inc. · Healthcare · United States · $174M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Codexis, Inc. is a leading company in enzyme engineering and biocatalysis, providing sustainable solutions for the pharmaceutical, food and beverage, and industrial sectors. The company possesses a proprietary CodeEvolver® enzyme engineering platform, allowing for rapid development of highly specific and efficient enzymes. It is a specialized biotechnology company at the forefront of enzyme engineering, providing critical biocatalytic solutions for greener and more efficient manufacturing.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 138.6M | 70.1M | 59.3M | 70.4M | -20.2% | 77.7M | 74.1M | 88.4M | 12.1% |
| EPS | -0.33 | -0.51 | -1.12 | -0.89 | -0.50 | — | -0.33 | -0.42 | -0.32 | — |
| Shares | — | 65.8M | 69.9M | 81.8M | 90.5M | +37.5% | 109.5M | — | — | — |
| Debt | — | 43.6M | 16.0M | 59.9M | 73.2M | 18.8% | 72.6M | — | — | — |
| Equity | — | 144.8M | 86.6M | 66.9M | 50.5M | -29.6% | — | — | — | — |
| Op CF | — | 11.3M | -52.6M | -49.4M | -19.4M | — | -10.4M | — | — | — |
| Inv CF | — | -13.6M | -4.9M | -57.0M | 23.5M | — | — | — | — | — |
| Fin CF | — | -0.6M | 8.2M | 60.5M | 27.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CDXS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CDXS | Codexis, Inc.(you) | $174M | 21 | Sell |
| NKTX | Nkarta, Inc. | $198M | 22 | Sell |
| NRXP | NRx Pharmaceuticals, Inc. | $154M | 23 | Sell |
| KRRO | Korro Bio, Inc. | $190M | 17 | Strong Sell |
| CUE | Cue Biopharma, Inc. | $203M | 16 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 13 | Strong Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 26 | Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%